Torrent Pharmaceuticals Limited

NSEI:TORNTPHARM Stock Report

Market Cap: ₹1.3t

Torrent Pharmaceuticals Past Earnings Performance

Past criteria checks 6/6

Torrent Pharmaceuticals has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 12.1% annually. Revenues have been growing at an average rate of 9.4% per year. Torrent Pharmaceuticals's return on equity is 25.3%, and it has net margins of 17.5%.

Key information

14.51%

Earnings growth rate

14.51%

EPS growth rate

Pharmaceuticals Industry Growth17.49%
Revenue growth rate9.45%
Return on equity25.33%
Net Margin17.47%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

Dec 03
If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 11
The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Price Is Out Of Tune With Earnings

Nov 03
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Price Is Out Of Tune With Earnings

Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?

Aug 21
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?

Torrent Pharmaceuticals Limited Just Missed EPS By 9.0%: Here's What Analysts Think Will Happen Next

Jul 31
Torrent Pharmaceuticals Limited Just Missed EPS By 9.0%: Here's What Analysts Think Will Happen Next

Pinning Down Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is Difficult Right Now

Jul 04
Pinning Down Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is Difficult Right Now

Should You Be Adding Torrent Pharmaceuticals (NSE:TORNTPHARM) To Your Watchlist Today?

Jun 13
Should You Be Adding Torrent Pharmaceuticals (NSE:TORNTPHARM) To Your Watchlist Today?

Torrent Pharmaceuticals' (NSE:TORNTPHARM) Dividend Will Be ₹6.00

May 23
Torrent Pharmaceuticals' (NSE:TORNTPHARM) Dividend Will Be ₹6.00

We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt With Ease

Mar 12
We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt With Ease

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Feb 19
Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Torrent Pharmaceuticals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Jan 28
Torrent Pharmaceuticals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

Dec 16
If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity

Revenue & Expenses Breakdown

How Torrent Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:TORNTPHARM Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 25122,48121,40324,0980
30 Jun 25118,35120,02323,2580
31 Mar 25115,16119,11322,7080
31 Dec 24113,01818,62421,6060
30 Sep 24112,23818,02421,0760
30 Jun 24109,95817,35420,6760
31 Mar 24107,27816,56420,1660
31 Dec 23104,74214,94219,6620
30 Sep 23102,33213,43218,9320
30 Jun 2398,64212,69217,8420
31 Mar 2396,20212,45217,0520
31 Dec 2292,5808,31216,2330
30 Sep 2288,7507,97215,8830
30 Jun 2287,2108,01215,8330
31 Mar 2285,0807,77215,4830
31 Dec 2183,15812,18915,2270
30 Sep 2182,02812,66914,9770
30 Jun 2180,82812,60914,7170
31 Mar 2180,04612,51914,5970
31 Dec 2080,14312,41714,3500
30 Sep 2079,85311,95714,2600
30 Jun 2079,73311,29714,2100
31 Mar 2079,39310,24714,4210
31 Dec 1978,4885,59314,3980
30 Sep 1979,3385,54314,5380
30 Jun 1978,2284,89314,3880
31 Mar 1976,7284,36314,0380
31 Dec 1875,1418,16113,7430
30 Sep 1869,8916,28112,7830
30 Jun 1865,1216,53112,1830
31 Mar 1859,4986,78111,3530
31 Dec 1756,7276,55610,6740
30 Sep 1756,3878,26610,2840
30 Jun 1756,3878,29610,0440
31 Mar 1758,1579,3369,9340
31 Dec 1659,15410,01410,2330
30 Sep 1660,14410,6249,9130
30 Jun 1662,74413,6449,3930
31 Mar 1666,66917,3328,4240
31 Dec 1563,31516,29918,6530
30 Sep 1559,60513,13918,5830
30 Jun 1554,8659,43918,7230
31 Mar 1546,5357,5098,7720
31 Dec 1447,2478,64916,5100

Quality Earnings: TORNTPHARM has high quality earnings.

Growing Profit Margin: TORNTPHARM's current net profit margins (17.5%) are higher than last year (16.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TORNTPHARM's earnings have grown by 14.5% per year over the past 5 years.

Accelerating Growth: TORNTPHARM's earnings growth over the past year (18.7%) exceeds its 5-year average (14.5% per year).

Earnings vs Industry: TORNTPHARM earnings growth over the past year (18.7%) exceeded the Pharmaceuticals industry 14.7%.

Return on Equity

High ROE: TORNTPHARM's Return on Equity (25.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/09 03:07
End of Day Share Price 2025/12/09 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Torrent Pharmaceuticals Limited is covered by 55 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pranav ChawlaAmbit Capital
Nitin BhasinAmbit Capital
Ashwin MehtaAmbit Capital